Pull to refresh
Logo
What Changed
Following Why Sign Up
FDA grants final approval to Handa's alternate-salt cancer drug OMCAZIO

FDA grants final approval to Handa's alternate-salt cancer drug OMCAZIO

Money Moves

Taiwan's Handa Pharmaceuticals clears US regulatory hurdles with a laurylsulfate salt of cabozantinib that patients can take with food

September 11th, 2026: Press release confirms OMCAZIO final approval

Overview

Updated Sep 11

The FDA cleared a Taiwanese drugmaker to sell an alternate-salt version of the $2.1 billion cancer drug cabozantinib in the United States. The final approval lands three days after a federal appeals court kept generic entry shut by upholding patents on the originator's salt form.

Handa Pharmaceuticals' OMCAZIO uses the laurylsulfate salt of cabozantinib, approved through Section 505(b)(2), an abbreviated FDA pathway that lets applicants rely on existing safety data plus their own bridging studies. It is bioequivalent to Exelixis's Cabometyx at a roughly 42% lower milligram dose and can be taken with or without food.

The FDA also denied a citizen petition from Exelixis that sought to block approval on safety grounds. Handa now faces the harder test of winning prescriptions in a market Cabometyx has dominated since 2016.

Why it matters

A $2.1 billion cancer franchise now has an FDA-approved rival patients can take with food, built on a salt switch that sidesteps the originator's patents.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

$2.11B
Cabometyx US market sales (2025)
Exelixis's cabozantinib franchise, the market OMCAZIO now enters.
42%
Lower milligram dose for bioequivalence
OMCAZIO reaches equal blood exposure with roughly 42% fewer milligrams than Cabometyx.
3
OMCAZIO capsule strengths
Available as 34.5 mg, 23 mg, and 11.5 mg capsules.
36 days
Tentative to final FDA approval
From July 29, 2026 tentative approval to September 3, 2026 final approval.

Voices

Curated perspectives — historical figures and your fellow readers.

Sign up to generate historical perspectives on this story.

Log in Sign Up

People Involved

Bill Liu
Bill Liu
Chairman and chief executive of Handa Pharmaceuticals
Leading OMCAZIO's US commercialization

Organizations Involved

Handa Pharmaceuticals, Inc.
Handa Pharmaceuticals, Inc.
Specialty pharmaceutical company (Taiwan Stock Exchange: 6620)
Developer of OMCAZIO

Taiwanese specialty drugmaker that developed OMCAZIO, an alternate-salt formulation of cabozantinib, through its wholly owned US subsidiary Handa Oncology.
Handa Oncology, LLC
Handa Oncology, LLC
US subsidiary
Named applicant for OMCAZIO's US approval

Handa Pharmaceuticals' wholly owned US subsidiary and the named applicant on OMCAZIO's FDA approval.
Exelixis, Inc.
Exelixis, Inc.
Biopharmaceutical company
Originator of Cabometyx; fought OMCAZIO approval

US biopharma that markets cabozantinib as Cabometyx; holds patents on the drug's malate salt and filed the citizen petition the FDA denied.
U.S. Food and Drug Administration
U.S. Food and Drug Administration
Federal regulator
Granted final approval to OMCAZIO

The US regulator that granted OMCAZIO final approval and denied Exelixis's citizen petition.

Timeline

November 2025 September 2026

8 events Latest: September 11th, 2026 · 2 months ago
Tap a bar to jump to that date

  1. Press release confirms OMCAZIO final approval

    Latest Statement

    Handa distributes a press release announcing OMCAZIO's FDA final approval and US commercial authorization.

  2. Handa discloses approval to Taiwan exchange

    Statement

    Handa files a material disclosure with the Taiwan Stock Exchange confirming the final approval.

  3. FDA grants final approval, denies petition

    Regulatory

    The FDA converts tentative approval to final, authorizing US commercialization, and denies Exelixis's citizen petition.

  4. Federal Circuit upholds malate salt patents

    Legal

    The appeals court keeps ANDA generic entry on cabozantinib's malate salt closed by upholding Exelixis's patents.

  5. Cabozantinib compound patent expires

    Legal

    The base compound patent covering cabozantinib lapses, removing one barrier to selling a competitive product.

  6. FDA grants tentative approval

    Regulatory

    The FDA finds OMCAZIO meets quality, safety, and efficacy standards, but patent protection blocks immediate marketing.

  7. Exelixis files citizen petition

    Legal

    Exelixis urges the FDA to reject Handa's application, arguing the alternate-salt drug raises new safety and effectiveness questions.

  8. FDA accepts Handa's OMCAZIO application

    Regulatory

    The FDA accepts the 505(b)(2) application for substantive review, setting a July 29, 2026 target action date.

Scenarios

1

Handa launches OMCAZIO in the US on its own

Likely Resolves by Q2 2027

Discussed by: Handa's public statements on its dual-track commercialization strategy

Handa has said it is preparing independent US sales while keeping licensing options open. A solo launch means building or contracting an oncology sales force and persuading oncologists to switch scripts from Cabometyx, leaning on the no-fasting and lower-dose story. The company has completed its regulatory milestones and says it is moving to commercial readiness.

2

Handa licenses US commercialization to a partner

Possible Resolves by Q2 2027

Discussed by: Handa's statements on keeping licensing conversations open

The other track Handa has flagged is licensing to a partner with existing oncology sales infrastructure. A deal would bring upfront and milestone payments and faster penetration of a market Cabometyx has dominated since 2016, at the cost of margin.

3

Exelixis sues Handa over patents

Possible Resolves by Q2 2027

Discussed by: Exelixis's citizen petition and its history of enforcing cabozantinib patents

Exelixis lost the citizen petition battle but could still sue Handa for infringement, arguing OMCAZIO violates method-of-treatment or dosing patents beyond the malate salt claims the Federal Circuit upheld. The central question is whether any Exelixis patent covers the laurylsulfate product itself.

4

OMCAZIO takes a double-digit share of the US cabozantinib market

Uncertain Resolves by Q1 2028

Discussed by: Market analysts tracking US oncology prescribing patterns

A successful launch would see OMCAZIO capture meaningful scripts from Cabometyx, helped by the no-fasting convenience and lower-dose equivalence. The benchmark is reaching at least 10% of quarterly US cabozantinib prescriptions or sales by market value.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

2000–2001

Prilosec to Nexium (2000–2001)

As AstraZeneca's blockbuster acid-reflux drug omeprazole (Prilosec) neared US patent expiry, the company launched esomeprazole (Nexium) in 2001. Nexium was the S-enantiomer, a mirror-image version of the same molecule, marketed as a distinct new drug with its own patent protection.

Then

Nexium became one of the best-selling drugs in the world as Prilosec went generic.

Now

The case became the template for product lifecycle management, where chemical variants extend commercial exclusivity beyond an original patent.

Why this matters now

It shows how a chemical modification of an approved drug can reshape market competition, the same logic Handa applied with a different salt form.

2002

Neupogen to Neulasta (2002)

Amgen's daily-injection cancer-support drug Neupogen (filgrastim) spawned pegfilgrastim (Neulasta) in 2002, a chemically modified version requiring one injection per chemotherapy cycle instead of daily shots.

Then

Neulasta extended Amgen's franchise for more than a decade on the strength of fewer injections.

Now

It demonstrated that dosing convenience alone can sustain a modified drug's market leadership.

Why this matters now

A formulation change that improves convenience can dominate an existing market, parallel to OMCAZIO's no-fasting advantage over Cabometyx.

1984

Section 505(b)(2) pathway created (1984)

The 1984 Hatch-Waxman Act created Section 505(b)(2), an abbreviated approval path where applicants can rely on published literature and the reference drug's safety and efficacy data instead of running full clinical trials of their own.

Then

The pathway opened the door to reformulations, new salts, new combinations, and new delivery routes.

Now

It became a standard tool for launching competitive versions of established drugs with far lower development cost and time.

Why this matters now

Handa used exactly this mechanism, bridging to Cabometyx's data while submitting its own bioequivalence studies for the new salt.

Sources

(7)
+1
Health Technology Net / ACCESS Newswire XPR Newsroom / ACCESS Newswire Morning Glory Sciences ACCESS Newswire Taiwan Stock Exchange disclosure (via OpenData) BigGo Finance Handa Pharmaceuticals